ReviewThrombosis and haemostasis2019
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Review in Thrombosis and haemostasis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 23 citations in OpenAlex.
- Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with Chronic Kidney Disease and Acute Myocardial Infarction: A Real-World Cohort Study.Cardiorenal medicine · 2026Article
- Antithrombotic therapy in diabetes: which, when, and for how long?European heart journal · 2021Review
- Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation.Journal of thrombosis and thrombolysis · 2020Article
- Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.Nature reviews. Cardiology · 2020Review
- Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations.Therapeutic advances in hematology · 2019Review
- Extended antithrombotic therapy for secondary prevention of cardiovascular events: A tool for pharmacists.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPCArticle
Corrections and comments
- Erratum issuedErratum.2019
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Antithrombotic treatment is a key component of secondary prevention following acute coronary syndromes (ACS). Although dual antiplatelet therapy is standard therapy post-ACS, duration of treatment is the subject of ongoing debate. Prolonged dual antiplatelet therapy in high-risk patients with history of myocardial infarction reduced the risk of recurrent myocardial infarction, stroke or cardiovascular death. Similarly, in patients with stable coronary artery disease, two-thirds of whom had a history of myocardial infarction, dual antithrombotic therapy with very-low-dose rivaroxaban and aspirin also resulted in improved ischaemic outcomes. In the absence of head-to-head comparison, choosing the most appropriate treatment strategy can be challenging, particularly when it comes to balancing the risks of ischaemia and bleeding. We aim to review the evidence for currently available antithrombotic treatments and provide a practical algorithm to aid the decision-making process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.